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OBJECTIVES: The aim of the present study was to investigate the prevalence of depression and adherence to
antiretroviral treatment in two groups of individuals: men who have sex with men (MSM) and men who have
sex with women (MSW).
METHODS: Two hundred and sixteen participants (MSM=116; MSW=100) who visited the Clinics Hospital of the
School of the Medicine of the University of Sa˜o Paulo completed two independent surveys (the BECK Depression
Inventory and an adherence self-declared questionnaire) to evaluate their depression status and adherence to
antiretroviral treatment, respectively.
RESULTS: The study highlighted a positive relationship between depression and low adherence to Highly Active
Antiretroviral Therapy in these patients regardless of age and sexual orientation. In addition, MSM subjects
were two times more prone than MSW subjects to develop depression symptoms. White or mixed race men
showed 7.6 times greater adherence to treatment than black men. The probability of complete adherence to
treatment was 3.8 times higher in non-depressed subjects than in depressed subjects regardless of their ethnicity.
The chance of developing depression was 4.17 times higher for an individual with non-adherent behavior than for
an adherent individual.
CONCLUSIONS: Individuals with low adherence rates have proportionally higher depression rates. Depressed
men tend to show less adherence to treatment. Black but not mixed race or white men show less adherence
to Highly Active Antiretroviral Therapy and have a greater chance of developing depression, which directly
interferes with adherence. The chances of developing depression are four times greater for a patient with non-
adherent behavior than for a patient with adherent behavior.
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’ INTRODUCTION
Globally, HIV/AIDS is a serious public health concern.
Brazil faces severe social implications due to an estimated
HIV-infected population of 700,000. Historically, two impor-
tant facts underscore the calamity of the AIDS epidemic—in
1995, AIDS was the cause of the highest number of deaths
worldwide, and the largest number of new HIV cases was
diagnosed in 1997. Due to a great deal of effort by the inter-
national community and the availability of advanced medical
care for infected patients, the infection rate has largely stabilized.
At present, HIV is considered a chronic condition that requires
a continuous and prolonged use of drugs (1).
Adherence to treatment and maintaining a relationship
with health services are key indicators of the success of the
medical management of chronic diseases (2). The degree of
adherence to treatment depends on the extent to which the
patient understands and agrees with the provided guide-
lines. In cases with low adherence, the patient may develop
opportunistic infections and experience daily discomfort or
recurrent episodes of minor viral infections, leading to poor
consequences in the individual’s life. An emerging major
public health problem is the possibility of transmission of a
multidrug-resistant virus (2).
Several authors have shown that poor adherence to drug
therapy has significantly reduced the well-known clinical
benefits for HIV-infected individuals, leading to a complete
failure of treatment and the patient’s death. Following 95%
of the proposed treatment scheme is the desired level of
adherence (3,4,5).DOI: 10.6061/clinics/2017(12)05
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Many studies have noted the need to monitor patients’
adherence statuses. The initial phase of treatment is considered
the most critical period for successful adherence. Therefore,
approaches including individualized care and constant
monitoring of the patient by a multidisciplinary team are
recommended (6).
Currently, 91% of adherence studies have been performed
in the United States and Europe, and few studies have
reported data from Brazil. Even the sparse Brazilian reports
suffer from limitations, because they have not been con-
ducted in accordance with international standards (5,7).
Therefore, monitoring adherence to antiretroviral treatment
at referral centers is an important method to identify those
at high risk for treatment failure and provide an early
intervention (6,2).
Drug efficacy is also determined by various psychological
factors. Depression, which is a common condition that affects
more than 350 million people worldwide according to the
World Health Organization, is directly associated with non-
adherence to HIV treatment (8,9) and is expected to be the
third leading cause of disability worldwide by 2020 (10).
Depression is a common mental health problem that is asso-
ciated with a decreased quality of life, productivity loss,
and family stress (Reviewed by 11). Depressive symptoms
are often managed by primary care physicians unless the
severity of the condition requires specialist psychiatric care
(Reviewed by 11). Some common features of depression
include the presence of an irritable mood accompanied by
somatic and cognitive changes that significantly affect the
individual’s capacity to function (12). Depression is char-
acterized by general feelings of sadness, anhedonia, avolition,
worthlessness, and hopelessness. Cognitive and neurovegeta-
tive symptoms, such as difficulty concentrating, memory
alterations, anorexia, and sleep disturbances, have also
been reported (12).
The high level of correlation between depression/suicide
and depression/non-adherence to treatment is disturbing for
care providers. Studies have suggested that depression is the
most common psychological disorder affecting HIV-infected
individuals (13). Moreover, depression and anxiety affect a
patient’s behaviors and consequently their adherence to treat-
ment due to apathy, hopelessness, self-neglect, and forgetful-
ness, which aggravates the scenario (14,15,16).
Failure to adopt the treatment in a proper manner has
been identified in HIV-positive individuals reporting at least
one episode of depression, which increases their chances of
developing further health problems (17) and risky behaviors
(13,18). Globally, people living with HIV/AIDS are affected
by depression two times as often as the general popula-
tion (9,19,20).
In addition, the frequency of depressive episodes has a
direct correlation with the chances of non-adherence to anti-
retroviral therapy (21). Changes in an individual’s behaviors
due to depression can also disrupt interpersonal relation-
ships and social networks, which negatively influences the
immune status and productive lifestyle and considerably
increase welfare-related problems (8,22).
Due to the scarce data available on the relationship between
depression and adherence to antiretroviral treatment in Brazil,
the present study aimed to investigate the prevalence of
depression among male HIV/AIDS patients classified as
men who have sex with men (MSM) and men who have sex
with women (MSW) in São Paulo city, which is the most
developed region of Brazil.
’ MATERIALS AND METHODS
Participants
A total of 216 men with HIV attending the Clinics Hospital
of the School of Medicine of the University of São Paulo
participated in the study. All participants were referred
for follow-up treatment by the local blood bank (Fundac¸ão
Pró-Sangue Hemocentro de São Paulo) after a positive
serology test for HIV. The data collection period was between
March 2014 and December 2015.
Procedure
A cohort of 304 HIV-positive men in active follow-up at
the Clinics Hospital of the Medical School of the University
of São Paulo was invited to participate in this study. Two
hundred and sixteen participants (71.05%) agreed to parti-
cipate after meeting the following inclusion criteria: HIV
status; minimum age of 18 years; and use of antiretroviral
drugs. The participants were divided into two groups (MSM
and MSW).
Ethics Committee
The study was approved by the Ethics Committee of the
Clinics Hospital of the School of Medicine of the University
of São Paulo (CAPPesq, number 473.230). The participants
consented to the use of survey data in the present analysis.
Questionnaires
The Beck Depression Inventory was applied to identify
possible depression symptoms among all subjects. The Beck
inventory is a self-administered questionnaire that consists
of 21 groups of statements. The inventory, which was pre-
viously validated for use among the Brazilian public, enables
the construction of a depression score for each participant
based on a self-report (23,17,18). To evaluate adherence,
one inventory was applied with functions similar to the inven-
tories adopted for the START (‘‘The Strategic Timing of Anti-
retroviral Treatment Study’’) and SMART (19,20) studies (24).
Statistical analysis
Descriptive statistics with means and standard deviations
(SDs) were reported for continuous variables, and frequen-
cies were reported for categorical variables. A two-way
contingency analysis (w2) was performed to assess whether a
categorical variable significantly differed between the two
groups (MSM and MSW), and Student’s t-test was performed
to compare continuous variables between the groups. The
statistical analysis was performed using logistic regression
for adherence and analysis of categorical data for depression.
The following variables were collected from each participant
and tested for both models: age group (40 years or younger
and 41 years or older); schooling (in years); ethnicity (white,
mixed, or black); viral load; CD4+ T lymphocyte count;
marital status (married, single, separated, or divorced); sexual
orientation (MSM or MSW); and mode of transmission of
disease (sexual contact with a person of the same sex or
with a person of the opposite sex, blood products, or others).
A model of the linear log class was used within the cate-
gorized data analysis to estimate the probability of depres-
sion. Initially, one linear log model was built to check which
variables were associated with the depression level. Sub-
sequently, the most parsimonious model was achieved using
adherence and age as variables. The model’s goodness of fit
(and that of the intermediate models resulting from models
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with feature removal) was measured using statistical ward
continuity.
Regarding the adherence model, logistic regression was
used to analyze the association between adherence to treat-
ment and other variables. All features were initially included
in the model, and the final and most parsimonious model
was achieved using stepwise selection with depression and
ethnicity as its variables. The quality of adjustment of the
model was checked using a residual envelope graph.
After quality adjustment for both models using a statistical
ward (categorical data) and envelope graph (logistic regres-
sion), the final analysis was performed using the R Studio
software.
The results of both models were expressed and interpreted
through odds ratios (ORs) and 95% confidence intervals (CIs)
for all features whether or not they were statistically signifi-
cant. The level of significance for all statistical tests was set
at 0.05.
Electronic data management
The database was developed using the Research Electronic
Data Capture (REDCap) tool hosted in our institution’s
(School of Medicine, University of São Paulo) web server.
This tool allowed validation, auditing, and export of the
study data(25).
’ RESULTS
Demographic and clinical laboratory data
Among the 216 HIV-infected men, 116 (53.7%) were MSM
and 100 (46.3%) were MSW (Table 1). The ethnicities of
the subjects were as follows: 70.4% white; 17.6% mixed; 8.8%
black; and 3.2% unknown (Table 1). The majority of the parti-
cipants in both groups were over 40 years of age. No signifi-
cant differences in ethnicity and age were observed between
the MSM and MSW. Similarly, schooling was identical for
both groups.
However, significant differences were found in the marital
status (po0.001), with 86.2% of the MSM and 38.0% of MSW
single and 5.1% of the MSM and 50.0% of the MSW married
(Table 1).
The transmission of infection occurred chiefly through
sexual intercourse with persons of the same sex (43.6%, with
rates of 73.3% and 9% for MSM and MSW, respectively),
Table 1 - Demographic data from 216 patients infected by HIV.
Variables MSM MSW Total *p-value CI 95% (msm – msw)
Mean age 44.6±11.98 48±10.39 46.2±11.37 0.026 [-6.38; -0.42]
Age in years
p40 39 (33.6%) 19 (19%) 58 (26.9%) 0.024 [2.2%; 27.1%]
X41 77 (66.4%) 81 (81%) 158 (73.1%) 0.024 [-27.1%; -2.2%]
Ethinicity
White 85 (73.3%) 67 (67%) 152 (70.4%) 0.39 [-7.0%; 19.4%]
Mixed 20 (17.2%) 18 (18%) 38 (17.6%) 1 [-11.7%; 10.2%]
Black 11 (9.5%) 8 (8%) 19 (8.8%) 0.87 [-6.9%; 9.9%]
W/information 0 (0%) 7 (7%) 7 (3.2%) 0.004 [-12.9%; -1.1%]
Marital Status
Single 100 (86.2%) 38 (38%) 138 (63.9%) o0.001 [35.9%; 60.5%]
Married 6 (5.1%) 50 (50%) 56 (25.9%) o0.001 [-56.4%; -33.3%]
Separated 1 (0.9%) 5 (5%) 6 (2.8%) 0.09 [-9.7%; 1.4%]
Divorced 8 (6.9%) 3 (3%) 11 (5.1%) 0.32 [-2.7%; 10.5%]
W/information 1 (0.9%) 4 (4%) 5 (2.3%) 0.18 [-8.3%; 2.0%]
*Education in years
until 05 8 (6.9%) 9 (9%) 17 (7.9%) 0.75 [-10,3%; 6,1%]
until 09 36 (31.1%) 40 (40%) 76 (35.2%) 0.22 [-22,7%; 4,7%]
more than 10 62 (53.4%) 41 (41%) 103 (47.7%) 0.09 [-1,7%; 26,6%]
W/information 10 (8.6%) 10 (10%) 20 (9.2%) 0.91 [-10,0%; 7,3%]
Transmission
*S.C.W.S.S.P. 85 (73.3%) 9 (9%) 94 (43.6%) o0.001 [53.5%; 75.0%]
*S.C.W.O.S.P. 4 (3.4%) 37 (37%) 41 (19%) o0.001 [-44.5%; -22.6%]
Blood 0 (0%) 3 (3%) 3 (1.4%) 0.10 [-7.3%; 12.7%]
Others 1 (0.9%) 4 (4%) 5 (2.3%) 0.18 [-8.3%; 2.0%]
Unknown 18 (15.5%) 32 (32%) 50 (23.1%) 0.007 [-28.6%; -4.3%]
W/information 8 (6.9%) 15 (15%) 23 (10.6%) 0.09 [-17.4%; 1.2%]
Lymphocytes T CD4+
o200 19 (16.4%) 20 (20%) 39 (18.1%) 0.60 [-14.9%; 7.6%]
200 - 350 7 (6%) 6 (6%) 13 (6%) 1 [-6.4%; 6.4%]
350 - 500 30 (25.9%) 20 (20%) 50 (23.1%) 0.39 [-6.3%; 18.0%]
4500 60 (51.7%) 54 (54%) 114 (52.8%) 0.84 [-16.6%; 12.0%]
Viral load HIV
0 - 10.000 112 (96.6%) 94 (94%) 206 (95.4%) 0.52 [-4.1%; 9.2%]
10.000 - 100.000 3 (2.6%) 5 (5%) 8 (3.7%) 0.48 [-8.5%; 3.7%]
41000.000 1 (0.8%) 1 (1%) 2 (0.9%) 1 [-2.9%; 2.6%]
*The p-values (Fisher Exact test) indicated here indicate whether HSM / MSM populations are different in age, ethnicity, marital status, education,
transmission, lymphocytes T CD4+ and viral load. There is no relation to the response variables (adherence and depression).
* in education item in this table, divided by educational cycles practiced in Brazil.
*MSM = Men who have sex with men
*MSW= Men who have sex with women
*S.C.W.S.S P.= Sexual contact with same sex partner
* S.C.W.O.S.P. = Sexual contact with opposite sex partner.
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whereas 19.0% of the infections were acquired via sexual
intercourse with persons of the opposite sex (3.4% and 37%
for MSM and MSW, respectively) (Table 1). A higher per-
centage of individuals in the MSW group than in the
MSM group did not know how they acquired the infection
(Table 1).
Clinical data indicate that 52.8% of all participants had
CD4+ lymphocyte counts4500 mm3, and 18.1% had counts
o200 mm3 (Table 1). The viral load was undetectable or
o10,000 copies in 95.4% of the participants (Table 1).
Depression and adherence
The Beck questionnaire revealed that 32.5% of the parti-
cipants in both groups had some level of depression (Table 2).
Importantly, 8.4% of the participants presented severe
symptoms of depression (Table 2). Almost all participants
(90.8%) declared adherence to the antiretroviral therapy
(Table 2).
Depression as a variable response
After dividing the variable response (depression) into four
categories (minimum or none, mild, moderate, and severe),
the probability of each category was estimated based on the
explanatory variables (see Table 3).
Table 3 shows the results of the final log-linear class model
from the categorized data analysis. The category of depres-
sion used as a reference was minimum or none.
Variables such as adherence (p=0.046), age (p=0.042), and
transmission (p=0.076) showed a greater correlation with
depression in the multivariate analysis. Since the sample size
might not be representative of all categories of depression,
considering p=0.07 statistically significant was acceptable.
The results showed that men younger than 40 years had a
2.9-fold higher chance of developing moderate depression
than older men. Men who acquired the disease due to sexual
contact with persons of the same sex had a 2.0-fold greater
chance of developing severe depression than men who acquired
the disease through sexual contact with the opposite sex.
Those reporting poor adherence to treatment had a 3.8-fold
higher chance of suffering from moderate depression than
those reporting complete adherence. The results are sum-
marized in Tables 3 and 4.
The goodness of fit of the model was validated using
statistical ward continuity (p=0.73). This test verified our
hypotheses and proved that the model was adequate, with a
high p-value indicating that the residues followed a normal
distribution with a mean of 0 and variance of 1 (Figure 1).
Table 2 - Absolute numbers and respective percent of depression by Beck depression inventory (BDI) and adherence data by START
questionnaire.
B.D.I. MSM MSW All *p-value CI 95% (msm – msw)
0 - 13 73/ (62.9%) 73/ (73%) 146/ (67.5%) 0.15 [-23.3%; 3.2%]
14 - 19 22/ (18.9%) 13/ (13%) 35/ (16.2%) 0.32 [-4.7%; 16.6%]
20 - 28 12/ (10.3%) 5/ (5%) 17/ (7.9%) 0.23 [-2.5%; 13.3%]
29 - 63 9/ (7.7%) 9/ (9%) 18/ (8.4%) 0.93 [-9.5%; 7.1%]
Adherence
All 106/ (91.4%) 90/ (90%) 196/ (90.8%) 0.91 [-7.3%; 10.1%]
Majority 7/ (6.0%) 6/ (6.0%) 13/ (6.0%) 1 [-6.4%; 6.4%]
Half 2/ (1.7%) 1/ (1.0%) 3/ (1.4%) 1 [-3.1%; 4.5%]
Few 0 2/ (2.0%) 2/ (0.9%) 0.21 [-5.6%; 1.7%]
None 1/ (0.9%) 1/ (1.0%) 2/ (0.9%) 1 [-2.8%; 2.6%]
B.D.I.
0 - 13 - Minimum depression
14 - 19 - Mild depression
20 - 28 - Moderate depression
29 - 63 - Severe depression.
ADHERENCE
All - Ingestion of all prescribed doses
Majority - Ingestion of most prescribed doses
Half - half doses intake
Few - Ingestion of a few doses
None - Do not eat the doses indicated.
Table 3 - Demonstration of the Log-linear class for categorized
data analysis regarding depression as a response variable related
to the other variables.
Variable
Depression
level p-value OR 95% CI
Age Mild 0.96 0.97 [0.32; 2.91]
Moderate 0.042 0.34 [0.12; 0.96]
Severe 0.27 0.64 [0.29; 1.40]
Viral Load Mild 0.77 1.38 [0.16; 12.13]
Moderate 0.73 1.46 [0.17; 12.88]
Severe 0.68 1.42 [0.27; 7.36]
Lymphocytes T CD4+ Mild 0.07 2.56 [0.92; 7.09]
Moderate 0.50 0.70 [0.25; 1.97]
Severe 0.68 0.85 [0.40; 1.79]
Marital status Mild 0.46 0.69 [0.26; 1.84]
Moderate 0.98 1.01 [0.35; 2.91]
Severe 0.88 1.06 [0.48; 2.33]
Education Mild 0.91 0.94 [0.35; 2.51]
Moderate 0.15 2.16 [0.76; 6.10]
Severe 0.99 0.99 [0.47; 2.09]
Transmission Mild 0.72 0.84 [0.31; 2.25]
Moderate 0.60 0.76 [0.27; 2.13]
Severe 0.076 0.51 [0.24; 1.07]
Orientation Mild 1.00 1.00 [0.38; 2.61]
Moderate 0.11 0.42 [0.14; 1.23]
Severe 0.17 0.59 [0.28; 1.28]
Ethinicity Mild 0.76 0.78 [0.16; 3.74]
Moderate 0.22 0.42 [0.11; 1.67]
Severe 0.25 3.32 [0.42; 26.00]
Adherence Mild 0.53 0.60 [0.12; 2.99]
Moderate 0.046 0.26 [0.07; 0.97]
Severe 0.43 0.61 [0.18; 2.09]
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Adherence as a variable response
The adherence and non-adherence parameters were ana-
lyzed by logistic regression. The probabilities were estimated
for each category by considering other variables (age, viral
load, CD4+ T lymphocyte count, marital status, education,
HIV transmission, and sexual orientation). The parameters
were shortened and validated through successive tests of the
likelihood ratio (with p=0.05). The results of the model
showed that ethnicity (p=0.0008) and depression (p=0.0134)
were significantly related to adherence, whereas the relation-
ships of the other variables were not significant [age (p=0.33),
viral load (p=0.26), CD4+ T lymphocyte count (p=0.5),
marital status (p=0.47), education (p=0.53), transmission
(p=0.28), and sexual orientation (p=0.37)] (Table 5).
The distribution of adherence based on ethnicity and
depression is shown in Table 6. Accordingly, white or mixed
race men with depression reported 90.6% adherence to anti-
retroviral therapy, whereas black men with depression reported
33.3% adherence to treatment. Our statistical analysis showed
that white or mixed race men were 7.7 times more likely
to adhere to treatment than black men. The probability of a
non-depressed subject adhering completely to the treatment
was 3.8 times higher than the probability of depressed sub-
jects adhering to treatment regardless of ethnicity.
’ DISCUSSION
The goal of our study was to evaluate the prevalence of
depression in men with HIV/AIDS who had sex with men
(MSM) or women (MSW) and its relationship with treatment
adherence. Our results showed that adherence did not depend
on age or sexual orientation; the overall adherence rate in
this study was 90.74%. Ninety-five percent of non-depressed
men adhered to treatment, whereas 86% of depressed indivi-
duals showed adherence. Black men showed less adherence
(68%) than white (93%) and mixed race men (97%). Regard-
less of sexual orientation, the non-adherents were 2.84 times
more likely to develop depression. Thus, depression has a
direct negative action on adherence.
Depression was the most commonly reported psycho-
logical disorder among our participants. In addition, being
in a constant state of depression might influence immune
responses (9,21,26). Notably, this disorder is largely under-
diagnosed in this population (27). Depression in an HIV-
infected individual has been reported to largely hinder the
patient’s life. In a study with 55 individuals, Porche and
Willis (2006) found that 64% of the participants were diagnosed
with depression, although only 42% reported symptoms (28).
Table 5 - Demonstration of the multivariate analysis regarding
adherence as a response variable related to the other variables
studied.
Variable p-value Odds Ratio 95% CI
Age 0.33 1.85 [0.61; 5.60]
Ethnicity 0.0008 7.68 [2.34; 25.21]
Marital status 0.47 1.6 [0.44; 5.78]
Education 0.53 0.98 [0.93; 1.04]
Transmission 0.28 2.18 [0.53; 8.94]
Sexual Orientation 0.37 0.5 [0.11; 2.26]
Lymphocytes T CD4+ 0.5 1.45 [0.53; 8.94]
Viral load HIV 0.26 0.35 [0.06; 2.17]
Depression 0.0134 3.81 [1.32; 11.02]
For the regression model for a variable adherence, the above results
for all variables tested. Among them, only ethnicity and depression are
statistically significant (po0.05). The results can be interpreted through
odds ratios and their respective confidence intervals.
The interpretation of the odds ratios indicates that, from the statistical
model, it is considered that black men have a 7.7 times greater chance of
not being adherent in relation to men of the other ethnicities. Men who
have any level of depression have a 3.8 times greater chance of not being
adherent compared to those without depression.
Table 6 - Observed distribution of adherence per ethnicity and
depression.
Variable Adherence
Ethinicity Depression Adherence non adherence Total
White/Mixed w/o depression 125 (94%) 8 (6%) 133
w depression 58 (90.6%) 6 (9.4%) 64
Black w/o depression 11 (84.6%) 2 (15.4%) 13
w depression 2 (33.3%) 4 (66.7%) 6
Figure 1 - The diagnosis of the logistic regression model. Since all
residues are within the confidence band of the expected
distribution, the model is well adjusted.
Table 4 - Chances of individual develop depression in the studied group. Observed distribution of depression per transmission and
adhrence.
Depression
Transmission Adherence Minimum Mild Moderate Severe Total
Same Sex Yes 54 (64.3%) 17 (20.2%) 7 (8.3%) 6 (7.1%) 84
No 4 (40%) 3 (30%) 1 (10%) 2 (20%) 10
Oposite Sex/Others Yes 82 (73.2%) 14 (12.5%) 6 (5.4%) 10 (8.9%) 112
No 6 (60%) 1 (10%) 3 (30%) 0 (0%) 10
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The most common symptoms of depression reported in
our survey were in agreement with studies from different
countries (29,30).
Investigations worldwide have revealed that the pre-
valence of depression is two to three times higher in HIV-
positive individuals than in the general population (31,33).
The depression rates in our sample were comparable
to those reported in other studies. However, no significant
differences were found between the groups regarding sexual
orientation, although the MSM group showed a higher
tendency for depression since they predominantly contracted
the disease by sexual contact with people of the same sex.
One main novel element in this study was that although
previous studies compared the state of depression between
groups of patients with HIV and those without (34), this
study performed a comparison between two subgroups of
HIV-infected individuals. Our results suggested that sexual
orientation had no significant influence on depression, whereas
age and adherence had detrimental effects on moderate
depression symptoms. Married men showed a lower rate of
depression than the other men. In line with this finding, the
group with the highest prevalence of depression was divorced
individuals. Importantly, single men who were infected through
intercourse with same-sex partners showed two times more
severe depression symptoms than men who were infected
through intercourse with partners of the opposite sex.
Previous studies have shown that HIV-infected women have
higher levels of depression than HIV-infected men (15,22,35,36).
A survey in Brazil reported by Mello et al. (2006) indicated
that the prevalence of depression in HIV-infected women
ranged from 25% to 45%. Interestingly, the percentage of
depression observed in the MSM group in our study was
comparable to that reported for HIV-positive women in other
studies (35,33,29).
Depression is widely thought to reduce the degree of adherence
to antiretroviral therapy (37,38). In contrast, our results indi-
cated that even depressed patients showed adequate adherence
to antiretroviral treatment.
Studies have confirmed that good adherence rates are
directly related to medical assertiveness, which encourages
the patient to establish a good relationship with health pro-
fessionals (24,39,40).
Different cohorts of HIV-infected patients reported an
average of 65.6% adherence to Highly Active Antiretroviral
Therapy (41,42). Similarly, in the present study, we observed
a high rate of adherence to antiretroviral treatment. We noted
that depression and adherence did not show any correlation
with sexual orientation. Another study reported that no sig-
nificant relationship existed between depression and non-
adherence to antiretroviral treatment (37). The high rates of
adherence among both groups can be attributed to the excellent
services offered by health professionals in our care setting.
Most patients in our cohort were under follow-up care for a
long time, which suggested that a consistent relationship was
a decisive factor for the success of antiretroviral treatment.
Many other studies have reached a similar conclusion (43,31).
The likelihood of adherence to antiretroviral treatment is
83% higher if symptoms of depression are identified and care
is provided. The risk of non-adherence increases by 35% among
those who do not receive any treatment for depression (30).
We observed a significant relationship between depression
and adherence. Most of the non-adherent patients presented
only milder forms of depression, because the multidisciplinary
treatment approach in our institution quickly and appropriately
addressed the psychological symptoms of depression in
patients.
Regarding the ethnicities of the patients, we found that
black men were less adherent to treatment than white and
mixed race men. The probability of non-depressed white or
mixed race men adhering to treatment was 96.7%; however,
the probability of adherence decreased to 88.5% in depressed
individuals. Conversely, the probability of adherence in non-
depressed black men was 79.2%, whereas the probability
decreased to 49.9% in depressed black men. These results
corroborate those of other studies showing black men have
lower adherence (44,45) and less of a propensity toward
adherence with antiretroviral therapy (46).
Studies on African-American men have indicated that
stigma, poor reliability on medical assistance, poor social
conditions, and psychosocial issues negatively impact the
care inherent for those with HIV-positive conditions (47,4).
Unfortunately, our study data did not consider the eco-
nomic statuses of the patients for analysis. Consideration of
the economic statuses would have allowed a better inter-
pretation of our findings on the population of African Brazilian
men living with HIV/AIDS.
The relationship between age, adherence, and moderate
depression was significant in our patient groups.
To the best of our knowledge, our study is the first to
report the prevalence of depression and adherence to anti-
retroviral treatment in HIV-positive men in São Paulo, which
is the largest city in South America. Our report showed
evidence that black men living with HIV/AIDS who had
same-sex partners needed more attention from a multidisciplin-
ary team regarding their depression statuses and reduced
adherence to antiretroviral treatment.
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